News

Turn bad into good fat
Enlarge image

ResearchSwitzerland

Turn bad into good fat

28.04.2013 - Swiss scientists have shown for the first time that brown and white fat cells in a living organism can be converted from one cell type to the other.

Using mice as model organisms, the research of the team under Christian Wolfrum from ETH Zurich provides a new approach for anti-obesity therapies. For the first time they demonstrated that energy storing white fat cells can be switched to energy-burning brown fat cells.

For their investigations, Wolfrum et al. made use of the observaton that both humans and mice can adapt to cold temperatures by forming brown fat cells within their white fat depots. These so-called "brite" fat cells (brown-in-white) are less common at warmer than at colder temperatures. To demonstrate whether brite fat cells are formed from white fat cells or other precursors the researchers generated mice with genetically labeled specific fat cells. Exposing them to the cold, the mice formed brite fat cells. After warm adaptation the fat tissue turned white again. The experiments proove that white fat cells can convert into brown fat cells and vice versa. As humans have the same type of cells as mice it is likely that the same process occurs in humans upon cold stimulation.

 The researchers now want to find pharmaceutical or nutritional triggers to convert the cells. According to Wolfrum, this would change the current paradigm of obesity treatment. "Current anti-obesity therapies target the energy intake side of the equation by controlling appetite and the uptake of nutrients", says Wolfrum. The pharmacological treatments that are available are not very efficient and usually are associated with side effects. In contrast, this novel approach to treat obesity would target the energy expenditure side of the equation by promoting brown fat formation. 

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/turn-bad-into-good-fat.html

BusinessGermany

19.09.2014 In order to concentrate on the life science business, German industry giant Bayer is splitting off its plastics subgroup as a separate company.

FinanceSwitzerland

18.09.2014 Swiss biopharma Cardiorentis has received a €45m investment from overseas investment firm Healthcare Royalty Partners in order to finance the registration for its heart drug.

PoliticsEU

15.09.2014 Jean Claude Juncker, the European Commission President-elect revealed his new Commissioners last week, whilst announcing a change in the units dealing with medicines, medical devices and health technology.

BiosimilarsGermanyFrance

12.09.2014 The 2011 collaboration of Boehringer Ingelheim and Eli Lilly is bearing fruit. An insulin biosimilar developed through the partnership has now been approved in Europe - the first-ever generic version of this class.

FinancingNetherlands

11.09.2014 Cystic fibrosis specialist Proqr Therapeutics has set the terms for its upcoming IPO at US-American stock exchange NASDAQ.

Clinical TrialsUKSweden

09.09.2014 In the midst of the hustle and bustle of the European Respiratory Society’s International Congress 2014, Astrazeneca quietly announced the disappointing results of its latest benralizumab study.

BusinessDenmark

04.09.2014 After their arthritis product’s Phase IIb failure, Novo Nordisk A/S is pulling out of all research and development activities within inflammatory disorders.

BusinessBelgiumIrelandSwitzerland

02.09.2014 In the face of declining revenue, Belgian biopharmaceutical company Thrombogenics has decided to spin out its cancer research and development activities.

ResearchUKSwitzerlandItaly

29.08.2014 Just a week ago, Glaxosmithkline defused the WHO’s claim that an Ebola vaccine could be ready by 2015. Now, the British company’s own candidate vaccine is to be rushed to human trials with the help of funding from an international consortium.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX2.69 EUR14.47%
  • BAYER112.70 EUR6.17%
  • CO.DON3.32 EUR5.40%

FLOP

  • SYNGENTA310.90 CHF-1.96%
  • SANTHERA88.05 CHF-1.23%
  • ADDEX3.10 CHF-0.96%

TOP

  • CO.DON3.32 EUR32.8%
  • PAION3.05 EUR27.1%
  • EPIGENOMICS3.83 EUR22.8%

FLOP

  • ADDEX3.10 CHF-22.5%
  • EVOTEC3.08 EUR-16.1%
  • MEDIGENE3.93 EUR-14.6%

TOP

  • SANTHERA88.05 CHF2058.1%
  • CO.DON3.32 EUR277.3%
  • PAION3.05 EUR202.0%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.09 CHF-40.0%
  • BIOFRONTERA2.20 EUR-39.7%

No liability assumed, Date: 18.09.2014